Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04372927 · ClinicalTrials.gov registry record · Phase 2
ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy
A Phase 2 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04372927 is a Phase 2 study that was terminated before completion, run by University of Washington. The registered enrollment target is 1 participants.
The verdict
NCT04372927, a Phase 2 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This phase II trial studies two questions in patients with stage III NSCLC: 1) does it improve cancer control to add the drug Durvalumab, a type of immunotherapy, earlier in the treatment course; and 2) by intensifying treatment with durvalumab, is it possible to avoid mediastinal radiation to decrease side effects, without decreasing cancer control?
Interventions
- DRUG Cisplatin
- DRUG Pemetrexed
- BIOLOGICAL Durvalumab
- DRUG Etoposide
- RADIATION Hypofractionated Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-12-10 |
| Est. Completion | 2022-04-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04372927
The ClinicalTrials.gov registry entry for NCT04372927 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT04372927 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04372927 about?
NCT04372927 is a clinical study titled "ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy". This phase II trial studies two questions in patients with stage III NSCLC: 1) does it improve cancer control to add the drug Durvalumab, a type of immunotherapy, earlier in the treatment course; and 2) by intensifying treatment with durvalumab, is it possible to avoid mediastinal radiation to decre...
What is the current status of trial NCT04372927?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2021-12-10. Estimated completion is 2022-04-23.
What interventions are being tested in trial NCT04372927?
The interventions under investigation include: Cisplatin (DRUG), Pemetrexed (DRUG), Durvalumab (BIOLOGICAL), Etoposide (DRUG), Hypofractionated Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT04372927?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.